Publications

  1. Mountjoy L, Jain T, Kunze KL, Khera N, Sproat LZ, Jennifer W, McCallen M, Leis JF, Noel P, Slack JL, Palmer J. Clinical outcomes with low dose anti-thymocyte globulin in patients undergoing matched unrelated donor allogeneic hematopoietic cell transplantation. Leuk Lymphoma. 2020 Aug; 61 (8):1996-2002 Epub 2020 Apr 13
    View PubMed
  2. Jain T, Kunze KL, Mountjoy L, Partain DK, Kosiorek H, Khera N, Hogan WJ, Roy V, Slack JL, Noel P, Fauble VDS, Leis JF, Sproat L, Tefferi A, Patnaik MM, Mesa RA, Palmer J. Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis. Blood Cancer J. 2020 Mar 10; 10 (3):36
    View PubMed
  3. Jain T, Kunze KL, Khetarpal BK, McCallen MR, Betcher JA, Ofori HT, Khera N, Slack JL, Leis JF, Sproat LZ, Noel P, Palmer J. Early fluctuations in busulfan levels with therapeutic dose monitoring during allogeneic stem cell transplantation: do they matter? Leuk Lymphoma. 2019 Aug; 60(8):2034-2041. Epub 2019 Jan 10.
    View PubMed
  4. Bolanos-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, Alousi AM, Antin JH, Arai S, Bickett K, Chen YB, Damon LE, Efebera YA, Geller NL, Giralt SA, Hari P, Holtan SG, Horowitz MM, Jacobsohn DA, Jones RJ, Liesveld JL, Logan BR, MacMillan ML, Mielcarek M, Noel P, Pidala J, Porter DL, Pusic I, Sobecks R, Solomon SR, Weisdorf DJ, Wu J, Pasquini MC, Koreth J. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematol. 2019 Mar; 6 (3):e132-e143
    View PubMed
  5. Jain T, Kunze KL, Temkit M, Partain DK, Patnaik MS, Slack JL, Khera N, Hogan WJ, Roy V, Noel P, Leis JF, Sproat LZ, Fauble V, Mesa RA, Palmer J. Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis. Bone Marrow Transplant. 2019 Feb; 54 (2):204-211 Epub 2018 May 24
    View PubMed
  6. Jain T, Kosiorek HE, Grys TE, Kung ST, Shah VS, Betcher JA, Slack JL, Leis JF, Khera N, Noel P, Palmer JM, Sproat LZ. Single dose versus multiple doses of rituximab for preemptive therapy of Epstein-Barr virus reactivation after hematopoietic cell transplantation. Leuk Lymphoma. 2019 Jan; 60 (1):110-117 Epub 2018 July 06
    View PubMed
  7. Gonzalez-Calle V, Slack A, Keane N, Luft S, Pearce KE, Ketterling RP, Jain T, Chirackal S, Reeder C, Mikhael J, Noel P, Mayo A, Adams RH, Ahmann G, Braggio E, Stewart AK, Bergsagel PL, Van Wier SA, Fonseca R. Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients. Ann Hematol. 2018 Aug; 97 (8):1453-1462 Epub 2018 Apr 06
    View PubMed
  8. Jain T, Kosiorek HE, Kung ST, Shah VS, Dueck AC, Gonzalez-Calle V, Luft S, Reeder CB, Adams R, Noel P, Larsen JT, Mikhael J, Bergsagel L, Stewart AK, Fonseca R. Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study. Clin Lymphoma Myeloma Leuk. 2018 Jul; 18 (7):486-492.e1 Epub 2018 May 04
    View PubMed
  9. Decook L, Chang YH, Slack J, Gastineau D, Leis J, Noel P, Palmer J, Sproat L, Sorror M, Khera N. Association of hematopoietic cell transplantation-specific comorbidity index with resource utilization after allogeneic transplantation. Bone Marrow Transplant. 2017 Jul; 52 (7):998-1002 Epub 2017 Apr 24
    View PubMed
  10. Rosenthal A, Dueck AC, Ansell S, Gano K, Conley C, Nowakowski GS, Camoriano J, Leis JF, Mikhael JR, Keith Stewart A, Stewart AK, Inwards D, Dingli D, Kumar S, Noel P, Gertz M, Porrata L, Russell S, Colgan J, Fonseca R, Habermann TM, Kapoor P, Buadi F, Leung N, Tiedemann R, Witzig TE, Reeder C. A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy. Am J Hematol. 2017 May; 92 (5):467-472 Epub 2017 Mar 22
    View PubMed
  11. Khera N, Chang YH, Slack J, Fauble V, Leis JF, Noel P, Sproat L, Palmer J, Adams R, Fitch T, Northfelt D, Guy M, Tilburt J, Mikhael J. Impact of race and ethnicity on outcomes and health care utilization after allogeneic hematopoietic cell transplantation. Leuk Lymphoma. 2015 Apr; 56 (4):987-92 Epub 2014 Aug 20
    View PubMed
  12. Khera N, Chang YH, Hashmi S, Slack J, Beebe T, Roy V, Noel P, Fauble V, Sproat L, Tilburt J, Leis JF, Mikhael J. Financial burden in recipients of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014 Sep; 20 (9):1375-81 Epub 2014 May 24
    View PubMed
  13. Chan EC, Bai Y, Kirshenbaum AS, Fischer ER, Simakova O, Bandara G, Scott LM, Wisch LB, Cantave D, Carter MC, Lewis JC, Noel P, Maric I, Gilfillan AM, Metcalfe DD, Wilson TM. Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype. J Allergy Clin Immunol. 2014 Jul; 134 (1):178-87 Epub 2014 Feb 28
    View PubMed
  14. Slack JL, Dueck AC, Fauble VD, Sproat LO, Reeder CB, Noel P, Khera N, Betcher JA, Klein JL, Leis JF, Adams RH. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch. Biol Blood Marrow Transplant. 2013 Aug; 19(8):1167-74. Epub 2013 May 7
    View PubMed
  15. Noel P, Cashen S, Patel B. Trauma-induced coagulopathy: from biology to therapy. Semin Hematol. 2013 Jul; 50 (3):259-69
    View PubMed
  16. Noel P, Mesa RA. Eosinophilic myeloid neoplasms. Curr Opin Hematol. 2013 Mar; 20(2):157-62.
    View PubMed
  17. Cherington C, Slack JL, Leis J, Adams RH, Reeder CB, Mikhael JR, Camoriano J, Noel P, Fauble V, Betcher J, Higgins MS, Gillette-Kent G, Tremblay LD, Peterson ME, Olsen JJ, Tibes R, Mesa RA. Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase. Leuk Res. 2012 Sep; 36(9):1147-51. Epub 2012 May 11.
    View PubMed
  18. Abdel-Wahab O, Pardanani A, Bernard OA, Finazzi G, Crispino JD, Gisslinger H, Kralovics R, Odenike O, Bhalla K, Gupta V, Barosi G, Gotlib J, Guglielmelli P, Kiladjian JJ, Noel P, Cazzola M, Vannucchi AM, Hoffman R, Barbui T, Thiele J, Van Etten, Mughal T, Tefferi A. Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium. Am J Hematol. 2012 May; 87(5):562-8. Epub 2012 Mar 28.
    View PubMed
  19. Gopalan RS, Arabia FA, Noel P, Chandrasekaran K. Hemolysis from aortic regurgitation mimicking pump thrombosis in a patient with a HeartMate II left ventricular assist device: a case report. ASAIO J. 2012 May-Jun; 58(3):278-80.
    View PubMed
  20. Noel P. Eosinophilic myeloid disorders. Semin Hematol. 2012 Apr; 49(2):120-7.
    View PubMed
  21. Tefferi A, Noel P, Hanson CA. Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology. J Mol Diagn. 2011 Sep; 13 (5):461-6 Epub 2011 June 30
    View PubMed
  22. Calvo KR, Vinh DC, Maric I, Wang W, Noel P, Stetler-Stevenson M, Arthur DC, Raffeld M, Dutra A, Pak E, Myung K, Hsu AP, Hickstein DD, Pittaluga S, Holland SM. Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implications. Haematologica. 2011 Aug; 96(8):1221-5. Epub 2011 Apr 20.
    View PubMed
  23. Noel P. Definition of remission, minimal residual disease, and relapse in hairy cell leukemia bone marrow biopsy histology and immunohistology specimens. Leuk Lymphoma. 2011 Jun; 52 Suppl 2:62-4 Epub 2011 Apr 04
    View PubMed
  24. Lee YN, Brandal S, Noel P, Mendell J, Wentzel E, McDevitt MA, Metcalfe D, Takamoto CM. Kit signaling regulates MITF expression through microRNAs in normal and malignant mast cell proliferation. Blood.2011;
  25. Meier ER, Byrnes C, Weissman M, Noel P, Luban NL, Miller JL. Expression patterns of fetal hemoglobin in sickle cell erythrocytes are both patient- and treatment-specific during childhood. Pediatr Blood Cancer. 2011 Jan; 56(1):103-9.
    View PubMed
  26. McDermott DH, De Ravin SS, Jun HS, Liu Q, Priel DA, Noel P, Takemoto CM, Ojode T, Paul SM, Dunsmore KP, Hilligoss D, Marquesen M, Ulrick J, Kuhns DB, Chou JY, Malech HL, Murphy PM. Severe congenital neutropenia resulting from G6PC3 deficiency with increased neutrophil CXCR4 expression and myelokathexis. Blood. 2010 Oct 14; 116(15):2793-802. Epub 2010 Jul 8.
    View PubMed
  27. Tanno T, Noel P, Miller JL. Growth differentiation factor 15 in erythroid health and disease. Curr Opin Hematol. 2010 May; 17(3):184-90.
    View PubMed
  28. Sportes C, Babb RR, Krumlauf MC, Hakim FT, Steinberg SM, Chow CK, Brown MR, Fleisher TA, Noel P, Maric I, Stetler-Stevenson M, Engel J, Buffet R, Morre M, Amato RJ, Pecora A, Mackall CL, Gress RE. Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin Cancer Res. 2010 Jan 15; 16(2):727-35. Epub 2010 Jan 12.
    View PubMed
  29. Uzzaman A, Maric I, Noel P, Kettelhut BV, Metcalfe DD, Carter MC. Pediatric-onset mastocytosis: a long term clinical follow-up and correlation with bone marrow histopathology. Pediatr Blood Cancer. 2009 Oct; 53(4):629-34.
    View PubMed
  30. Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, Fitzgerald DJ, Wilson WH, Pastan I. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol. 2009 Jun 20; 27(18):2983-90. Epub 2009 May 04.
    View PubMed
  31. Bhanu NV, Lee YT, Oneal PA, Gantt NM, Aerbajinai W, Noel P, Thomas CJ, Miller JL. Inhibition of erythroblast growth and fetal hemoglobin production by ribofuranose-substituted adenosine derivatives. Biochim Biophys Acta. 2008 Sep; 1782(9):504-10. Epub 2008 Jun 30.
    View PubMed
  32. Lahortiga I, Akin C, Cools J, Wilson TM, Mentens N, Arthur DC, Maric I, Noel P, Kocabas C, Marynen P, Lessin LS, Wlodarska I, Robyn J, Metcalfe DD. Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion. Haematologica. 2008 Jan; 93(1):49-56.
    View PubMed
  33. Klion AD, Robyn J, Maric I, Fu W, Schmid L, Lemery S, Noel P, Law MA, Hartsell M, Talar-Williams C, Fay MP, Dunbar CE, Nutman TB. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. Blood. 2007 Nov 15; 110(10):3552-6. Epub 2007 Aug 20.
    View PubMed
  34. Akin C, Scott LM, Kocabas CN, Kushnir-Sukhov N, Brittain E, Noel P, Metcalfe DD. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxis. Blood. 2007 Oct 1; 110(7):2331-3. Epub 2007 Jul 16.
    View PubMed
  35. Maric I, Robyn J, Metcalfe DD, Fay MP, Carter M, Wilson T, Fu W, Stoddard J, Scott L, Hartsell M, Kirshenbaum A, Akin C, Nutman TB, Noel P, Klion AD. KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. J Allergy Clin Immunol. 2007 Sep; 120(3):680-7. Epub 2007 Jul 12.
    View PubMed
  36. Kim YJ, Dale JK, Noel P, Brown MR, Nutman TB, Straus SE, Klion AD. Eosinophilia is associated with a higher mortality rate among patients with autoimmune lymphoproliferative syndrome. Am J Hematol. 2007 Jul; 82(7):615-24.
    View PubMed
  37. Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT, Verstovsek S, Dupriez B, Silver RT, Odenike O, Cortes J, Wadleigh M, Solberg LA Jr, Camoriano JK, Gisslinger H, Noel P, Thiele J, Vardiman JW, Hoffman R, Cross NC, Gilliland DG, Kantarjian H, IWG for Myelofibrosis Research and Treatment (IWG-MRT). International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 2006 Sep 1; 108 (5):1497-503 Epub 2006 May 04
    View PubMed
  38. Kreitman RJ, Squires DR, Stetler-Stevenson M, Noel P, FitzGerald DJ, Wilson WH, Pastan I. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol. 2005 Sep 20; 23(27):6719-29. Epub 2005 Aug 01.
    View PubMed
  39. Bhanu NV, Trice TA, Lee YT, Gantt NM, Oneal P, Schwartz JD, Noel P, Miller JL. A sustained and pancellular reversal of gamma-globin gene silencing in adult human erythroid precursor cells. Blood. 2005 Jan 1; 105(1):387-93. Epub 2004 Sep 14.
    View PubMed
  40. Robyn J, Noel P, Wlodarska I, Choksi M, O'neal P, Arthur D, Dunbar C, Nutman T, Klion A. Imatinib-responsive hypereosinophilia in a patient with B cell ALL. Leuk Lymphoma. 2004 Dec; 45(12):2497-501.
    View PubMed
  41. Klion AD, Law MA, Noel P, Kim YJ, Haverty TP, Nutman TB. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood. 2004 Apr 15; 103(8):2939-41. Epub 2003 Dec 24.
    View PubMed
  42. Klion AD, Robyn J, Akin C, Noel P, Brown M, Law M, Metcalfe DD, Dunbar C, Nutman TB. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood. 2004 Jan 15; 103(2):473-8. Epub 2003 Sep 22.
    View PubMed
  43. Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J, Metcalfe DD, Nutman TB. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood. 2003 Jun 15; 101(12):4660-6. Epub 2003 Apr 03.
    View PubMed
  44. Haddad SA, Winer KK, Gupta A, Chakrabarti S, Noel P, Klein HG. A puzzling case of anemia. Transfusion. 2002 Dec; 42(12):1610-3.
    View PubMed
  45. Litzow MR, Repoussis PD, Schroeder G, Schembri-Wismayer D, Batts KP, Anderson PM, Arndt CA, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, Noel P, Solberg LA Jr, Letendre L, Hoagland HC. Veno-occlusive disease of the liver after blood and marrow transplantation: analysis of pre- and post-transplant risk factors associated with severity and results of therapy with tissue plasminogen activator. Leuk Lymphoma. 2002 Nov; 43 (11):2099-107
    View PubMed
  46. Akin C, Jaffe ES, Raffeld M, Kirshenbaum AS, Daley T, Noel P, Metcalfe DD. An immunohistochemical study of the bone marrow lesions of systemic mastocytosis: expression of stem cell factor by lesional mast cells. Am J Clin Pathol. 2002 Aug; 118(2):242-7.
    View PubMed
  47. Wojda U, Noel P, Miller JL. Fetal and adult hemoglobin production during adult erythropoiesis: coordinate expression correlates with cell proliferation. Blood. 2002 Apr 15; 99(8):3005-13.
    View PubMed
  48. Letendre L, Noel P, Noel P, White WL, Tefferi A, Litzow MR, Li CY, Schroeder G. Treatment of unfavorable myelodysplastic syndrome with all-trans-retinoic acid and subcutaneous Ara C. Leuk Res. 1999 Sep; 23 (9):811-5
    View PubMed
  49. Harold KL, Schlinkert RT, Mann DK, Reeder CB, Noel P, Fitch TR, Braich TA, Camoriano JK. Long-term results of laparoscopic splenectomy for immune thrombocytopenic purpura. Mayo Clin Proc. 1999 Jan; 74(1):37-9.
    View PubMed
  50. Letendre L, Noel P, Noel P, Litzow MR, Hoagland HC, Tefferi A. Treatment of acute myelogenous leukemia in the older patient with attenuated high-dose ara-C. Am J Clin Oncol. 1998 Apr; 21 (2):142-4
    View PubMed
  51. Goldberg SL, Noel P, Klumpp TR, Noel P, Dewald GW. The erythroid leukemias: a comparative study of erythroleukemia (FAB M6) and Di Guglielmo disease. Am J Clin Oncol. 1998 Feb; 21 (1):42-7
    View PubMed
  52. Tefferi A, Litzow MR, Noel P, Noel P, Dewald GW. Chronic granulocytic leukemia: recent information on pathogenesis, diagnosis, and disease monitoring. Mayo Clin Proc. 1997 May; 72 (5):445-52
    View PubMed
  53. Stocker J, Bureau M, Cassar N, Noel P, deLeon A, Desjardins P. Usefulness of placental echolocalization in the third trimester. Union du Canada. 1997; 106:1161-3.
  54. Letendre L, Noel P, Noel P, Tefferi A, Solberg LA Jr, Gastineau DA, Hoagland HC. Continuous infusion etoposide/carboplatin for treatment of refractory acute leukemia. Am J Clin Oncol. 1995 Oct; 18 (5):382-4
    View PubMed
  55. Tefferi A, Silverstein MN, Noel P. Agnogenic myeloid metaplasia. Semin Oncol. 1995 Aug; 22(4):327-33.
    View PubMed
  56. Gertz MA, Pineda AA, Chen M, Letendre L, Greipp P, Witzig TE, Garton JP, Inwards D, Litzow M, Tefferi A, Kyle RA, Noel P. High-dose chemotherapy followed by peripheral stem cell transplantation in patients with refractory and relapsing multiple myeloma. Am J Med Sciences. 1995; 809:152-61.
  57. Ho TC, Tefferi A, Su JQ, Litzow MR, Hoagland HC, Noel P, Noel P. Acute lymphocytic leukemia in adults: a retrospective study and analysis of current management options. Mayo Clin Proc. 1994 Oct; 69 (10):937-48
    View PubMed
  58. Tefferi A, Mathew P, Noel P. The 5q- syndrome: a scientific and clinical update. Leuk Lymphoma. 1994 Aug; 14 (5-6):375-8
    View PubMed
  59. Call TG, Noel P, Noel P, Habermann TM, Beard CM, O'Fallon WM, Kurland LT. Incidence of leukemia in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc. 1994 Apr; 69 (4):315-22
    View PubMed
  60. Call TG, Phyliky RL, Noel P, Noel P, Habermann TM, Beard CM, O'Fallon WM, Kurland LT. Incidence of chronic lymphocytic leukemia in Olmsted County, Minnesota, 1935 through 1989, with emphasis on changes in initial stage at diagnosis. Mayo Clin Proc. 1994 Apr; 69 (4):323-8
    View PubMed
  61. Ho TC, Tefferi A, Su J, Hoagland HC, Noel P. Adult acute lymphocytic leukemia: A retrospective study and analysis of management options. Mayo Clin Proc. 1994; 69:937-48.
  62. Gertz MA, Kyle RA, Noel P. Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenstrom's macroglobulinemia. J Clin Oncol. 1993 May; 11: (5)914-20.
    View PubMed
  63. Gertz MA, Noel P, Noel P, Kyle RA. Second malignancies after chemotherapy and transplantation. Crit Rev Oncol Hematol. 1993 Apr; 14 (2):107-25
    View PubMed
  64. Noel P, Noel P, Tefferi A, Pierre RV, Jenkins RB, Dewald GW. Karyotypic analysis in primary myelodysplastic syndromes. Blood Rev. 1993 Mar; 7 (1):10-8
    View PubMed
  65. Mathew P, Tefferi A, Dewald GW, Goldberg SL, Su J, Hoagland HC, Noel P. The 5q- syndrome: a single-institution study of 43 consecutive patients. Blood. 1993 Feb 15; 81 (4):1040-5
    View PubMed
  66. Rosen CB, Ng CS, Moore SB, Batts KP, Santrach PJ, Noel P, Wiesner RH, Krom RAF. Clinical and pathological features of graft-versus-host disease after liver transplantation: a case report and review of the literature. Clin Transplant. 1993; 7:52-58.
  67. Menke DM, Colon-Otero G, Cockerill KJ, Jenkins RB, Noel P, Pierre RV, Noel P. Refractory thrombocytopenia. A myelodysplastic syndrome that may mimic immune thrombocytopenic purpura. Am J Clin Pathol. 1992 Nov; 98 (5):502-10
    View PubMed
  68. Goldberg SL, Tefferi A, Rummans TA, Chen MG, Solberg LA, Noel P. Post-irradiation somnolence syndrome in an adult patient following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1992 Jun; 9(6):499-501.
    View PubMed
  69. Graham DL, Tefferi A, Letendre L, Gastineau DA, Hoagland HC, Noel P, Noel P. Cytogenetic and molecular detection of residual leukemic cells after allogeneic bone marrow transplantation in chronic granulocytic leukemia. Mayo Clin Proc. 1992 Feb; 67 (2):123-7
    View PubMed
  70. Letendre L, Hoagland HC, Moore SB, Chen MG, Gastineau DA, Gertz MA, Habermann TM, Litzow MR, Noel P, Noel P, Solberg LA Jr. Mayo Clinic experience with allogeneic and syngeneic bone marrow transplantation, 1982 through 1990. Mayo Clin Proc. 1992 Feb; 67 (2):109-16
    View PubMed
  71. Noel P, Noel P, Solberg LA Jr. Myelodysplastic syndromes. Pathogenesis, diagnosis and treatment. Crit Rev Oncol Hematol. 1992; 12 (3):193-215
    View PubMed
  72. Jenkins RB, LeBeau MM, Krauer WJ, Borell TJ, Stalboerger PG, Davis EM, Penland L, Fernald A, Schaid DJ, Noel P, Dewald GW. Interphase fluorescence in situ hybridization: A sensitive method for trisomy 8 detection in bone marrow specimens. Blood. 1992; 79:3307-15.
  73. Noel P, Noel P. Management of patients with myelodysplastic syndromes. Mayo Clin Proc. 1991 May; 66 (5):485-97
    View PubMed
  74. Noel P, Noel P, Kyle RA. Plasma cell leukemia: an evaluation of response to therapy. Am J Med. 1987 Dec; 83 (6):1062-8
    View PubMed
  75. Cournoyer D, Noel P, Schmidt MA, Dewald GW. Trisomy 9 in hematologic disorders: possible association with primary thrombocytosis. Cancer Genet Cytogenet. 1987 Jul; 27(1):73-8.
    View PubMed
  76. Noel P, Kyle RA. Monoclonal proteins in chronic lymphocytic leukemia. Am J Clin Pathol. 1987 Mar; 87(3):385-8.
    View PubMed
  77. Dewald GW, Noel P, Dahl RJ, Spurbeck JL. Chromosome abnormalities in malignant hematologic disorders. Mayo Clin Proc. 1985 Oct; 60(10):675-89.
    View PubMed